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Julio Venditti, MD, Julio Chertcoff, MD, and Domingo Chimondeguy, MD
Introduction: The tumor, node, metastasis (TNM) system has been
recognized internationally as the standard for staging disease exten-
sion, but despite the improvements of the 1997/2002 international
staging system, there may be marked differences in postoperative
5-year survival rates within each stage. There is controversy about
the impact of tumor size itself as a variable unrelated to stage.
The objective of this study was to analyze the influence of
tumor size on the survival in patients with surgically resected
non-small cell lung carcinoma (NSCLC).
Methods: Between August 1985 and January 2006, 400 patients
underwent pulmonary resection with a curative intention for non-
small cell lung carcinoma. Patients were excluded if they had received
neoadjuvant chemotherapy. The clinicopathological records of each
patient were examined for prognostic factors such as age, sex, right or
left side cancer, histology, tumor location, tumor size, clinical nodal
stage number, and distribution of metastatic nodes.
Results: Operative mortality was 2.2% for lobectomy and 18% for
pneumonectomy (p  0.05). Adenocarcinoma was the most com-
mon type (n  245, 61.2%). Surgery was considered a complete
resection in 341 patients (85.2%). When only patients without
neoplastic hilar or mediastinal metastases (pN0) were included, the
difference in survival was significantly different in terms of tumor
size (log rank 28.46, p  0.0001). Univariate analysis for the group
of pN0 patients showed survival was not significantly affected by
age, sex, side, or adenocarcinoma histology. In the multivariate
analysis, tumor size and the T factor were found to have maintained
its independent prognostic effects on overall survival. Among pa-
tients with pN0 tumors smaller that 15 mm in diameter, 5-year
survival was 95% whereas patients with tumors bigger than 16 mm
in diameter had a 5-year survival of 65% (p  0.0001).
Conclusion: In conclusion, our data suggest that tumors over 15 mm
are associated with shorter 5-year survival in all TNM stages.
Current TNM categories are not sufficiently discriminatory and the
T factor requires to be reevaluated in further revisions of the TNM
classification.
Key Words: Non-small cell lung cancer, TNM classification, Me-
diastinal metastases.
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The tumor, node, metastasis (TNM) system has been rec-ognized internationally as the standard for staging disease
extension. It has been revised repeatedly over the last 30
years. The last revision was the sixth edition in 2002 and
remained unchanged since the fifth edition, by the Interna-
tional Union against Cancer (IUCC) and the American Joint
Committee on Cancer.1–3 Changes included in previous revi-
sions comprise the following: subdivision of stages I and II
into A and B, and addition of T3N0M0 to stage IIB. Despite
the improvements of the 1997/2002 international staging
system, there may be marked differences in postoperative
5-year survival rates within each stage. Currently, efforts are
being made to collect data to generate the seventh edition of
the TNM Classification of Malignant Tumors what is due to
be published early in 2009.4
The availability of more accurate imaging methods
allows now the detection of much smaller lesions. Tumor size
is a factor that has not changed since the initial staging system
of 1973 and the cutoff value of 3 cm is still in use to
discriminate between T1 and T2 tumors. However, contro-
versy has arisen over the impact of tumor size itself as a
variable unrelated to stage and a potential subdivision of
stage I in terms of tumor size has been considered.5–8 In fact,
the prognostic effect of tumor size in patients without in-
volvement of mediastinal lymph nodes (pathologic N0) has
not been clearly defined.9
Tumor size may also impact on the degree of local and
regional spread. It may mean that even in the absence of
enlarged lymph nodes in the computed tomography (CT)
scan, larger tumors could require invasive staging to exclude
mediastinal invasion.10 Although mediastinoscopy is cur-
rently suggested in the presence of a negative CT scan for
staging “large” tumors and adenocarcinomas, the exact im-
pact of histology and size of the primary lesion on regional
invasion still needs to be determined.
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The objective of this study was to analyze the influence
of tumor size on the survival in patients with surgically
resected non-small cell lung carcinoma (NSCLC). Our hy-
pothesis is that tumor size is an independent variable and that
risk of mortality increases with the increase of the tumor size
in every TNM stage of NSCLC.
MATERIALS AND METHODS
Between August 1985 and January 2006, 400 patients
underwent pulmonary resection with a curative intention for
NSCLC in the British Hospital in Buenos Aires. Patients
were excluded if they had exhibited small cell lung cancer or
a rare histologic type or if they had been included in a
neoadjuvant chemotherapy protocol. Patients were included
only after institutional review board approval. They were
retrospectively analyzed and all data were obtained from the
medical records. Survival status was obtained from telephone
interview and/or medical records.
Preoperative staging was performed according to the
TNM classification system of the International Union Against
Cancer using chest CT and abdominal CT or ultrasonography
in all patients. Brain CT or magnetic resonance imaging was
done only in case of clinical suspicion of brain metastases. In
cases of uncertain clinical or radiologic findings, further
examinations were performed to exclude extrapulmonary
metastases. Mediastinal and hilar lymph node status was
assessed as positive if the chest CT showed that the shorter
axis of any node was larger than 1.0 cm. Positron emission
tomography (PET) scan was not routinely performed. Medi-
astinoscopy has not been performed routinely in this series
unless the CT scan demonstrated mediastinal lymph node
enlargement. The clinicopathological records of each patient
were examined for prognostic factors such as age, sex, right
or left side cancer, histology, tumor location (upper or lower),
tumor size, cN number, and distribution of metastatic nodes.
All surgeries were performed by the same three surger-
ies and with the same sampling techniques. In all the patients
intrapulmonary nodes (groups 11,12, and 13) and hiliar nodes
(group 10) were sampled. For right thoracotomies sampling
of groups 7, 4R and 2R was performed in every case and for
left thoracotomies sampling included groups 5, 6, and 7. For
pneumonectomies and lower lobectomies sampling of groups
8 and 9 was included. All the cases antedated 1997 were
reviewed and classified according the new Mountain’s node
map. After surgery a final pathologic stage was stated based
on the operative findings. Histologic typing was determined
according to the World Health Organization classification.11
Lymph nodes were numbered and classified following Moun-
tain’s classification.12
Surgical resection was considered complete if all of the
following criteria were present: free resection margins proved
microscopically; systematic nodal dissection or lobe-specific
systematic nodal dissection; no extracapsular nodal extension
of the tumor; and the highest mediastinal node removed were
negative.13
The postoperative follow-up of patients was based on
regular visits, quarterly chest radiographs and a yearly chest
CT. Patients with operative or inhospital mortality, defined as
death occurring within 30 days after the operation or during
hospitalization, respectively, were included in this study.
Disease-free interval was defined as the difference between
the day of surgery and the date of the first recurrence or, in the
absence of recurrence, the last day of follow-up.
Statistical Analysis
Statistical analysis was performed using SPSS 13.0
statistical software. The analysis of differences in categorical
outcomes was determined using the 2 test or Fisher exact
test. Logistic regression models were used to ascertain the
association between individual factors and survival. Proba-
bilities of disease free survival rates were estimated using the
Kaplan–Meier method. Cox proportional hazards regression
models were used to ascertain the association between indi-
vidual factors and survival. Their joint effect was assessed in
a multivariable Cox analysis. Statistical significance was
assumed at p 0.05.14 The selection of a 15-mm cutoff value
was based on previous reports suggesting that resected tu-
mors smaller than 1.5 cm have better survival in stage IA.6,7
RESULTS
Four hundred patients were included (298 males, 74.5%,
median age 61.1  9.9 years). Median follow-up was 44.7
months (rank, 1–229 months). In the first decade (1985–1995),
142 were treated and in the second period (1996–2006)
patients included were 248.
A solid parenchymal opacity (n  268, 67.0%) and an
indeterminate lung nodule (n  122, 30.5%) were the most
common radiologic findings. The tumor was right-sided in
235 (58.7%), and peripheral in 292 patients (73.0%). Lobec-
tomy was performed in 301 patients (75.2%) and pneumo-
nectomy in 84 patients (21.0%). The remaining procedures
were bilobectomies (n  12) and multiple excisions. The
length of stay in the intensive care unit was 1.18  3.8 days
and hospital stay was 3.9  5.9 days long. Complications
occurred in 118 patients (29.5%). Operative mortality was
2.2% for lobectomy and 18% for pneumonectomy (p 0.05).
Clinical staging of patients is shown in Table 1. Patients in
stage IV were nine and they had fully resected solitary brain
metastases and locally circumscribed disease and were con-
sidered surgically treatable.
Adenocarcinoma was the most common type (n  245,
61.2%) (Table 2). Surgery was considered a complete resec-
tion in 341 patients (85.2%).
TABLE 1. Clinical TNM Staging Distribution of Patients
Clinical Stage n Percent
IA 124 31.0
IB 159 39.8
IIA 2 0.5
IIB 52 13.0
IIIA 47 11.8
IIIB 7 1.8
IV 9 2.3
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Recurrences were seen in 137 patients during follow-
up. Distant recurrences were the most common (n  99,
72.3%), with 13 cases of unrelated second tumors (9.5%).
Survival according pathologic TNM stages is shown in
Table 3, and survival for pathologic stages is shown in Figure 1.
The 5-year survival of pathologic stage IA was 85.9%. When
only patients without neoplastic hilar, mediastinal, or distant
metastases (pN0M0) and with a complete resection were
included, the difference in survival was significantly different
in terms of tumor size (log rank 6167, p  0.013) (Figure 2).
Univariate analysis for the group of pN0 patients showed
survival was not significantly affected by age, sex, side, or
adenocarcinoma histology. Survival was shorter when the T
factor was higher and the tumor size was larger (Table 4). In
the multivariate analysis, tumor size and the T factor were
found to have maintained its independent prognostic effects
on overall survival (Table 5). Among patients with pN0
tumors smaller that 15 mm in diameter, 5-year survival was
95% whereas patients with tumors bigger than 16 mm in
diameter had a 5-year survival of 65% (p  0.0001).
DISCUSSION
The current study shows an increased relative risk of
lung cancer mortality that correlates with tumor size in
patients with different TNM stages of resected non-small cell
lung carcinoma.
TNM stage is the most important prognostic factor in
resected NSCLC15,16 but in the last few years, research has
begun to focus on the influence of tumor size, even within the
same stage.1–5,7,8 This concern has been somehow reflected in
the 1997 reclassification of stages, with the subdivision of
stage I into IA (T1: tumors 3 cm or less in its greatest
diameter) and IB (T2, tumors larger than 3 cm).3 This
restaging resulted in survival differences throughout several
studies.7,17 Nevertheless, controversy remains about using 3
cm as the cutoff value (maintained by Mountain’s classifica-
FIGURE 1. Survival according pathologic staging of NSCLC
(n  400).
FIGURE 2. Survival according the size of the
tumor (n  400).
TABLE 2. Population Distribution by Hystologic Type (n  400)
Histology n Percent
Adenocarcinoma 245 61.3
Squamous 92 23
Bronchioloalveolar carcinoma 19 4.7
Adenosquamous 6 1.5
Large cell carcinoma 38 9.5
TABLE 3. Two- and 5-Year Survival by Pathological Stage
Stage n 2-yr Survival (%) 5-yr Survival (%)
IA 95 96 85
IB 103 77 62
IIA 8 85 57
IIB 66 69 62
IIIA 86 66 37
IIIB 28 62 33
IV 14 35 11
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tion) to define tumor size, as it may prove to be inadequate to
predict differences in survival. It becomes particularly rele-
vant now that the efforts to achieve early diagnosis are
allowing the diagnosis of very small tumors.
Several studies have reported tumor size may have an
independent predictive value on survival in stage I patients.
Birim et al.18 studied 130 patients with stage I NSCLC and
concluded that a tumor smaller than 2 cm in diameter predicts
a longer survival, and Riquet et al.19 have found a significant
difference in survival for resected T1N0M0 NSCLC depend-
ing on tumor size (5-year survival, 77, 62.8, and 62.9% for
tumors measuring 0.5–1 cm, 1.1–2 cm, and 2.1–3 cm, respec-
tively). Nevertheless, these findings are not consistent and
other researchers have not identified an independent effect of
tumor size on survival.6,20,21 In a previous study in a very
homogeneous group of patients (T1N0M0 tumors), Lyons
et al.22 reported that patients with stage I tumors measuring less
than 1.5 cm in diameter had a better survival suggesting that
tumor size is an independent predictive variable that defines
different categories of stage IA. That would be especially im-
portant to better define candidates for future studies on adjuvant
chemotherapy whose results are still very contradicting and
result in different recommendations about adjuvant chemother-
apy for stage I in different association’s guidelines.23–25 The
different results suggesting evidence or absence of evidence
of decreased risk of recurrence in patients with stage I
receiving chemotherapy26–30 may be dependent on the appar-
ent homogeneity of the population studied (stages IA and IB),
which in fact may be not so homogeneous if T1 tumors are
different when they are smaller. This could also explain the
5-year survival differences reported on this population, which
has been published from 9031 to 63%.32
The impact of tumor size seems not to be restricted to
small tumors and has been also shown in larger tumors. In
this regard, it has been suggested that stages IIA and IB
should be merged into one unique category.33 In our pN0
patients, the multivariate analysis has revealed that tumor size
and the T factor are the only independent factors associated
with shorter survival (Table 5). The T categories “less than 3
cm” and “more than 3 cm” seems to be too broad supporting
the need of a new revision of lung cancer staging system. In
that direction, the International Association for the Study of
Lung Cancer established its Lung Cancer Staging Project in
1998. The recommendations of this committee for changes to
the T, N, and M descriptors include additional cutoffs for
tumor size, with tumors more than 7 cm moving from T2 to
T3 and the possibility that T2b N0 M0 cases should be moved
from stage IB to stage IIA, T2a N1 M0 cases from stage IIB
to stage IIA, and T4 N0–1 M0 cases from stage IIIB to stage
IIIA. Such changes, if accepted, will involve a reassessment
of existing treatment algorithms.4,34
In our patients, survival following the traditional TNM
system showed similar figures to those reported in many
series5,6,17,35 although for stage pIIIA survival was 37%,
TABLE 4. Univariate Analysis of Survival in N0 Tumours
Variable N0 5-yr Survival (%) Log Rank Relative Risk (95% CI) p
Side
Right 142 67 0.88 1039 (0603–1790) 0.890
Left 95 74
Gender
Female 60 63 0.63 1158 (0634–2116) 0.633
Male 177 72
Age
60 yr 110 70 0.82 1060 (0632–1779) 0.824
60 yr 127 69
Histology
Adenocarcinoma 162 72 0.104 1549 (0910–2638) 0.107
Others 75 64
Size—T factor
T1 97 84 0.001 2977 (1654–5356) 0.000
T2-3-4 140 58
Size 1.5 cm
1.5 cm 36 95 0.0007 13,717 (1898–99,117) 0.000
1.6 cm 201 65
TABLE 5. Multivariate Analysis of Survival in Patients with Pathological Stage N0 Tumoursa
Factor Favorable Nonfavorable Relative Risk CI 95% p
T postoperative T1 T2-3-4 2026 1112–3702 0.021
Size 1.5 cm 1.5 cm 1.6 cm 8955 1194–67,130 0.033
a Analyzed factors: age, sex, right or left side, tumor location, histology, postoperative T, and tumor size smaller than 1.5 cm.
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around 10% higher than the survival reported by Goya et al.
(19.3%)36, Naruke et al.7 (23.6%), and Jassem et al.33 (15%).
Whether this represents a more strict selection of patients for
surgery, ethnic differences or heterogeneity in the different
series containing tumors of different sizes in the same stage is
rather unclear.
In conclusion, our data suggest that tumors over 15 mm
are associated with an increased risk of mediastinal metasta-
ses and with shorter 5-year survival in all TNM categories.
Current TNM categories are not sufficiently discriminatory
and the T factor requires to be reevaluated in further revisions
of the TNM classification.
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